



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Company Statement on Site 5 – API facility, Visakhapatnam

“The U.S. Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024. Four observations were cited at the end of the Inspection, which we will be addressing within the stipulated time.

Biocon stands committed to Quality, Safety & Efficacy of the products manufactured.”